Nihal joined F-Prime in 2013 and is a Partner based in London. He focuses on therapeutics companies across modalities and indication areas, as well as AI for drug discovery and healthcare.

Nihal is a founding investor and Board member at CHARM Therapeutics and AviadoBio, and a lead or co-lead Series A investor and Board member at T-Therapeutics, Dirigent Bio and Antlia Bioscience. He also sits on the Boards of Immutrin and AvenCell, and serves as a Board observer at Leyden Labs, Curie Bio and Elucidata.

Nihal is a founder, co-inventor and Board member at Raksha Therapeutics. He was a founding team member at Orchard Therapeutics (NASDAQ: ORTX; acquired by Kyowa Kirin), and was part of the deal teams for Sana Biotechnology (NASDAQ: SANA), Adaptimmune (NASDAQ: ADAP), Oviva, NodThera, Proximie and RIGImmune.

Nihal graduated from the University of Cambridge with an MA and MB BChir with distinction, and is a Member of the Royal College of Physicians. Before joining F-Prime, he worked as a strategy consultant at BCG and as an academic physician at Oxford University and UCL Hospitals.